Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Kalaris Therapeutics (Nasdaq: KLRS) announced that management will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kalaris Therapeutics (Nasdaq: KLRS) announced that management will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference.
Presentation details: Matthew Feinsod, Chief Medical Officer, will present on Wednesday, December 3, 2025 from 11:30–11:55 AM ET at Florida Atlantic University in Boca Raton, FL. Management will be available for one-on-one meetings by arrangement with conference representatives.
Details
News Market Reaction – KLRS
On Nov 24, the day this news came out, KLRS closed 7.99% below the previous close.
Data tracked by StockTitan Argus for the Nov 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 21st Annual Emerging Growth Equity Conference.
Details:
- Type: Company presentation
- Speakers: Matthew Feinsod, Chief Medical Officer
- Date: Wednesday, December 3, 2025
- Time: 11:30 - 11:55 am ET
- Location: Florida Atlantic University, Boca Raton, FL
Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
About Kalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
For more information, visit www.kalaristx.com.
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275547
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.